Gyroscope wanted to refine the fluidic control elements of its innovative Orbit SDS™ medical device and approached TTP to identify potential ways to achieve this.
Context
Gyroscope wanted to refine the fluidic control elements of its innovative Orbit SDS medical device, which enables precise microinjection into the eye for conditions such as dry age-related macular degeneration (AMD).
Solution
TTP’s experience of microfluidics, tolerance analysis, micro-prototyping and manufacturing came together to demonstrate enhanced fluidic and dosing performance with prototyped parts within the tight space constraints of Gyroscope’s device.
Result
TTP’s work gave Gyroscope the confidence to commit to creating moulded components and transfer to manufacture for the new concept.
Gyroscope (now a Novartis Company) has developed world-leading products for delivery of gene therapy to the subretinal space of the eye without the need for a vitrectomy or retinotomy.
Gyroscope wanted to refine the fluidic control elements of its innovative Orbit SDS medical device and approached TTP to identify potential ways to achieve this.
TTP reviewed the fluid control functionality of the device and generated alternative solutions for fluid control and sealing. Using an analytical approach, we were able to recommend a preferred solution from a number of concepts and to define the required tolerances to meet Gyroscope’s performance requirements. The use of an analytical approach also minimised the need for design iterations and enabled us to quickly create proof-of-concept test pieces for Gyroscope.
TTP then used a combination of rapidly prototyped parts and machined components to simulate final moulded parts that incorporated our understanding of manufacturing processes, tolerances and materials to provide compatibility with existing components of Gyroscope’s device.
These sample devices supported more detailed testing at TTP and Gyroscope, including accelerated aging and of overall fluidic and dosing performance using a test protocol and an absorbance assay developed by TTP.
When we received the new moulded parts incorporating TTP’s recommendations, all of them performed as intended and within specification. We were really excited.
Justin Creel
Vice President of Device Development
By combining analytical design approaches with deep knowledge of medical devices and manufacturing techniques, TTP was able to give Gyroscope the confidence to create moulded components to improve their ground-breaking medical device.
About TTP's Drug Delivery Team
From blank sheet to clinical reality, TTP's Drug Delivery team creates groundbreaking solutions to solve the toughest drug delivery challenges. With deep engineering, human factors, and scientific expertise, we guide you through every stage of drug delivery device development - from early exploration to manufacturing and final launch. Backed by an extensive track record we expertly navigate constraints to develop robust, efficient, scalable devices - enabling the delivery of transformative therapies and enhanced patient experiences.
